AUTHORS
Larissa Cardoso Zanetti, PhD, Caroline Suzuki2, Cleyson Barros3, Jamile Ramos4, Thiago Giove Mitsugi5, Erica Vidal6, Lays Trajano7, Ingrid Souza8, Julia Benincasa9, Oswaldo Okamoto, PhD10, Luisa Augusto11, Raquel de Melo Alves Paiva, PhD12, Bruno Matuck13, Nelson Hamerschlak Sr, MD PhD14, Lucila Nassif Kerbauy, MD, PhD15
AFFILIATIONS
1 Einstein Hospital Israelita, SAO PAULO, Brazil
2 Einstein Hospital Israelita, SAO PAULO, Brazil
3 Einstein Hospital Israelita, SAO PAULO, Brazil
4 Einstein Hospital Israelita, SAO PAULO, Brazil
5 Einstein Hospital Israelita, SAO PAULO, Brazil
6 Einstein Hospital Israelita, SAO PAULO, Brazil
7 Einstein Hospital Israelita, SAO PAULO, Brazil
8 Einstein Hospital Israelita, SAO PAULO, Brazil
9 Einstein Hospital Israelita, SAO PAULO, Brazil
10 Human Genome and Stem Cell Research Center, Department of Genetics and Evolutionary Biology, Biosciences Institute, University of São Paulo (USP), São Paulo, Brazil., Sao Paulo, Brazil
11 Einstein Hospital Israelita, SAO PAULO, Brazil
12 Einstein Hospital Israelita, SAO PAULO, Brazil
13 Einstein Hospital Israelita, SAO PAULO, Brazil, Faculdade de Medicina da Universidade de São Paulo, Departamento de Patologia, Brazil, Sao Paulo, Brazil, Wellcome Sanger Institute, Somatic Genomics Programme, Hixon, UK., Hixon, United Kingdom
14 Einstein Hospital Israelita, SAO PAULO, Brazil
15 Einstein Hospital Israelita, SAO PAULO, Brazil
ABSTRACT
Background
BCMA-directed CAR-T therapy has improved outcomes in relapsed/refractory multiple myeloma (MM), yet durable remissions remain limited by insufficient CAR-T persistence. Constitutive IL-15 expression enhances CAR-T expansion and persistence, although its in vivo safety remains incompletely understood. We directly compared an academic second-generation BCMA CAR-T (B4C) with a fourth-generation IL-15-secreting BCMA CAR-T (B4CI) in xenograft models of MM to evaluate antitumor efficacy, persistence, and treatment-related toxicity.
Methods
NSG mice were conditioned with busulfan and engrafted with luciferase-expressing MM.1S cells before treatment with saline, untransduced T cells (UT), B4C, or B4CI CAR-T cells (5×10⁶ or 2.5×10⁶ cells/mouse; n=4–5/group). Tumor progression was monitored by bioluminescence imaging, body weight, and a modified murine GVHD clinical score (0–10). Biodistribution of human CD45⁺ and CD3⁺CAR⁺ cells was assessed in spleen, bone marrow, liver, lung, and peripheral blood. Histopathological toxicity was assessed by conventional H&E and AI-assisted digital pathology using Cellpose-SAM whole-slide nuclear segmentation with quantitative morphometric analysis. Antigen-independent toxicity was evaluated in tumor-free NSG mice. Serum IL-15, IFN-γ, TNF-α, and IL-10 were quantified by multiplex assay.
Results
Both CAR-T products demonstrated comparable manufacturing, viability, antigen-specific cytokine production, and cytotoxicity against BCMA-positive MM cells, with no activity against BCMA-negative targets. In vivo, B4C achieved durable disease control, with 60% overall survival at study completion and 40% of mice remaining disease-free beyond 120 days while maintaining stable body weight and low GVHD clinical scores (mean 1.6). IL-15 armoring further enhanced efficacy, with B4CI inducing complete tumor eradication in 100% of treated animals. However, complete tumor clearance was accompanied by progressive GVHD-like toxicity, with a 4.5-fold higher clinical score than B4C (7.2 vs. 1.6), resulting in universal mortality approximately 5 weeks after infusion despite sustained tumor eradication. Reducing the CAR-T dose delayed, but did not prevent, toxicity. High-dose B4CI also induced weight loss and mortality in tumor-free NSG mice, demonstrating antigen-independent toxicity. B4CI exhibited significantly greater in vivo persistence, with increased human CD45⁺ cell accumulation in bone marrow (9.9×10⁴ cells; p<0.001 vs. B4C), spleen, liver, and lung. Consistent with these findings, AI-assisted digital pathology revealed markedly increased pulmonary and hepatic mononuclear infiltration, characterized by higher nuclear density and enrichment of lymphocyte-sized nuclei. Detectable circulating IL-15 in the absence of increased IFN-γ, TNF-α, or IL-10 argued against classical cytokine release syndrome and instead supported sustained IL-15-driven immune expansion and tissue infiltration as the likely basis of the observed toxicity.
Conclusions
Constitutive IL-15 expression enhanced BCMA CAR-T persistence and enabled complete tumor eradication but promoted antigen-independent GVHD-like toxicity associated with extensive tissue infiltration demonstrated by AI-based quantitative pathology. These findings support strategies to regulate IL-15 expression in order to preserve its potent antitumor activity while improving safety. In contrast, the academic second-generation BCMA CAR-T achieved durable long-term disease control with a favorable safety profile, supporting complementary use of both platforms in distinct clinical settings. Mechanistic studies using TCR-knockout IL-15-armored BCMA CAR-T cells are currently underway to determine whether the observed toxicity is TCR-dependent, providing definitive validation of its xenogeneic GVHD origin.
DISCLOSURES
Larissa Cardoso Zanetti, PhD: No relevant conflicts of interest to declare.